

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 12, 2016**

---

**SORRENTO THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**001-36150**  
(Commission  
File Number)

**33-0344842**  
(IRS Employer  
Identification No.)

**9380 Judicial Drive**  
**San Diego, CA 92121**  
(Address of principal executive offices)

**Registrant's telephone number, including area code: (858) 210-3700**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On September 12, 2016, Sorrento Therapeutics, Inc. (the “Company”) entered into a new lease agreement (the “Lease Agreement”) for its San Diego, California headquarters. The eight year and nine month office building lease between the Company and HCP Life Science REIT, Inc. is for approximately 76,687 square feet of office and lab space in San Diego.

The initial term of the lease is estimated to commence on March 1, 2017. The Company will be obligated to pay an average of approximately \$3.1 million in annual rent over the term of the lease.

Pursuant to the Lease Agreement, beginning not more than fifteen months prior to and not less than twelve months prior to lease expiration, the Company has the option to extend the lease for an additional five-year term at then current market rates.

The foregoing is only a brief description of certain of the terms of the Lease Agreement, does not purport to be complete and is qualified in its entirety by reference to the Agreement that will be filed as an exhibit to our quarterly report on Form 10-Q for the quarter ending September 30, 2016.

**Item 8.01 Other Events.**

On September 13, 2016, the Company announced that Miranda Toledano has been appointed Executive Vice President of Corporate Development of the Company and President of LA Cell, the Company’s Joint Venture with City of Hope. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press release dated September 13, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 13, 2016

SORRENTO THERAPEUTICS, INC.

By: /s/ Henry Ji  
Name: Henry Ji  
Title: President and Chief Executive Officer

## **Sorrento Appoints Miranda Toledano As Executive Vice President of Corporate Development, and President of LA Cell**

SAN DIEGO, September 13, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases, today announced that Miranda Toledano has been appointed Executive Vice President of Corporate Development of Sorrento and President of LA Cell, Sorrento's Joint Venture with City of Hope.

“We are very excited that Miranda has joined our executive team,” said Dr. Henry Ji, President & CEO of Sorrento. “Miranda brings a unique combination of fundamental knowledge and transactional experience in our key therapeutic areas which will be instrumental in crafting Sorrento's corporate strategy and accelerating our goals for LA Cell.”

Ms. Toledano joins Sorrento with 18 years of principal investment, financing and strategic advisory experience in the biopharmaceutical sector. Since 2012, Miranda served as Head of Healthcare Investment Banking at MLV & Co., now an FBR company, where she completed over 110 IPO and follow on equity offerings totaling over \$4 billion in aggregate value. Prior to joining MLV, Miranda served in the investment group of Royalty Pharma where she focused on acquiring best in class biologic therapeutics targeting oncology, auto-immune and neurodegenerative indications. From 1998 to 2003, Miranda served as a Senior Manager at Ernst & Young (Israel) where she established the Life Sciences Corporate Finance group. Miranda received a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

“I am thrilled to be joining Sorrento at this critical juncture in its history. Sorrento has amassed world class capabilities in generating highly differentiated, novel antibody and cell based product candidates which are poised to make a real difference across critical indications where patients are underserved. LA Cell's platform is disruptive in that it uniquely enables the penetration of large molecules such as antibodies, peptides, and modified DNA into disease cells. We are looking to apply this technology to specifically modulate formerly “undruggable” targets known to the evolution of cancer, infectious and metabolic diseases.”

### **About Sorrento Therapeutics, Inc.**

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases. Sorrento's lead products are late-stage biosimilar and biobetter antibodies, RTX for intractable cancer pain, as well as clinical CAR-T and CAR-NK therapies targeting solid tumors.

### **Forward-Looking Statements**

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento's and its subsidiaries' technologies and collaborations; Sorrento's ability to leverage the expertise of its

employees and partners to assist the company in the execution of its strategies; and Sorrento's prospects. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries' technologies and prospects; risks related to seeking regulatory approvals and conducting clinical trials; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2015, as amended, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

© 2016 Sorrento Therapeutics, Inc. All Rights Reserved.